Economic Impact of Multiplex Point-of-Care Testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium: Development of a Modeling Framework

Author(s)

Stephanie Earnshaw, PhD1, Cheryl McDade, -1, Christopher Dodoo, MS2, Zune Huynh, MD2, Katherine Zhang, MS, PharmD1, Susan N. Chang, PharmD2;
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Roche Molecular Systems, Inc., Pleasanton, CA, USA

Presentation Documents

OBJECTIVES: Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG) are sexually transmitted pathogens that often present as infections with similar symptoms, posing diagnostic challenges for clinicians. Inappropriately treated or untreated sexually transmitted infections (STIs) can lead to substantial costs in terms of unnecessary antibiotic use, additional physician visits, and even downstream complications such as pelvic inflammatory disease and infertility. Innovative, multiplex point-of-care testing may improve care thereby reducing costs and improving outcomes particularly associated with antibiotic stewardship. We set out to develop a decision modeling framework that assesses the economic impact of multiplex point-of-care testing for CT, NG, and MG compared to current standard care practice (laboratory-based testing and/or treatment without testing).
METHODS: We reviewed the literature to characterize the unmet needs, disease prevalence, burden, and existing clinical and economic data. The influence of diagnostics at different points in the treatment pathway was considered. This was used to create a patient pathway and unmet needs conceptual framework, which was validated with experts and advisors.
RESULTS: A decision-tree modeling framework was developed to assess the economic impact of multiplex point-of-care testing for CT, NG, and MG compared with current standard practice. Data inputs incorporated into the model included pathogen epidemiology (reported cases), percentage of infections with inappropriate treatment, antibiotic use, sequelae rates, costs, and quality-of-life. This framework was able to capture improvement of antibiotic stewardship and associated costs while measuring the impact on disease sequelae and the need for physician visits associated with subsequent care.
CONCLUSIONS: Innovative diagnostic solutions are urgently needed to address sexually transmitted infections. Having the proper decision modeling framework to assess the impact of being able to provide rapid results of multiplex testing to guide clinical decision-making and appropriate treatment at the place of care is important for understanding antibiotic stewardship and overall disease burden.

Conference/Value in Health Info

2025-05, ISPOR 2025, Montréal, Quebec, CA

Value in Health, Volume 28, Issue S1

Code

EE94

Topic

Economic Evaluation

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Reproductive & Sexual Health

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×